LBF20308PG01: Difference between revisions
No edit summary |
No edit summary |
||
| (14 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR1726 | |LipidBank=XPR1726 | ||
|LipidMaps=LMFA03010020 | |LipidMaps=LMFA03010020 | ||
|SysName=11- | |SysName=(cis-5,trans-12)-11-Oxo-15S-hydroxy-prosta-5,9,12-trien-1-oic acid | ||
|Common Name=&&Delta^{12}-Prostaglandin J_2&&11- | |Common Name=&&Delta^{12}- Prostaglandin J_2&&(5Z,12E)-11-Oxo-15S-hydroxy-prosta-5,9,12-trien-1-oic acid&& | ||
|Source= Delta ^{12}-PGJ2 is a decomposition product of PGD2 in the presence of albumin.[[Reference:Fitzpatrick_FA:Wynalda_MA:,J. Biol. Chem.,1983,258,11713|{{RelationTable/GetFirstAuthor|Reference:Fitzpatrick_FA:Wynalda_MA:,J. Biol. Chem.,1983,258,11713}}]] | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity= Delta ^{12}-PGJ2 has antitumor and antibiral activity, inhibiting growth of cultured L1210 cells with an IC50 of 0.7 mu g/ml.[[Reference:Kato_T:Fukushima_M:Kurozumi_S:Noyori_R:,Cancer Res.,1986,46,3538|{{RelationTable/GetFirstAuthor|Reference:Kato_T:Fukushima_M:Kurozumi_S:Noyori_R:,Cancer Res.,1986,46,3538}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 09:03, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1726 |
| LipidMaps | LMFA03010020 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20308PG01 |
| Δ12- Prostaglandin J2 | |
|---|---|
| |
| Structural Information | |
| (cis-5,trans-12)-11-Oxo-15S-hydroxy-prosta-5,9,12-trien-1-oic acid | |
| |
| Formula | C20H30O4 |
| Exact Mass | 334.21440944799997 |
| Average Mass | 334.4498 |
| SMILES | C(CC[C@@H](O)CC=C(C(=O)1)[C@@H](CC=CCCCC(O)=O)C=C1)CC |
| Physicochemical Information | |
| Delta ^{12}-PGJ2 is a decomposition product of PGD2 in the presence of albumin. Fitzpatrick_FA et al. | |
| Delta ^{12}-PGJ2 has antitumor and antibiral activity, inhibiting growth of cultured L1210 cells with an IC50 of 0.7 mu g/ml. Kato_T et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
